AANP Family Nurse Practitioner (FNP) Certification ExamEvaluationHard
A 45-year-old male with Type 2 Diabetes is monitoring his blood glucose levels. His fasting blood glucose readings have consistently been between 130-150 mg/dL over the past two weeks, despite adherence to his current diet and metformin 1000 mg twice daily. His last HbA1c was 7.8% three months ago. Which of the following modifications is most appropriate at this time?
- AAdd a sulfonylurea (e.g., glipizide) to his regimen.
- BInitiate basal insulin therapy.
- CIncrease metformin to 1500 mg twice daily.
- DRefer to an endocrinologist for advanced diabetes management.
Show answer & explanationAnswer & explanation
Correct answer: A. Add a sulfonylurea (e.g., glipizide) to his regimen.
The patient's fasting blood glucose and HbA1c indicate that his diabetes is not adequately controlled on metformin monotherapy. According to current guidelines for Type 2 Diabetes management, if HbA1c remains elevated despite maximal tolerated metformin, adding a second oral agent, such as a sulfonylurea, is a common and appropriate next step before considering insulin in most cases.
Why the other options are wrong
- B. While insulin is an option, it is generally considered after combination oral therapy has been tried or if HbA1c is significantly higher (e.g., >9%), or if symptoms of hyperglycemia are severe.
- C. The maximum recommended daily dose for metformin is typically 2000-2550 mg. While he's on 2000mg/day, increasing it further is unlikely to provide significant additional benefit and might increase side effects, making adding a second agent more effective.
- D. Referring to an endocrinologist is an option for complex cases, but managing this common progression of Type 2 Diabetes is within the FNP's scope of practice.
Step-Up Therapy for Type 2 Diabetes
When metformin monotherapy fails to achieve glycemic targets, adding a second agent from a different class (e.g., sulfonylurea, DPP-4 inhibitor, SGLT2 inhibitor, GLP-1 receptor agonist) is the next step.
- HbA1c target is typically <7% for most adults.
- Metformin is first-line pharmacotherapy.
- Choice of second agent depends on patient factors, comorbidities, and cost.
Memory trick: Metformin's maxed? Add a friend, then check again!